These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 25154787)

  • 21. Hepatic steatosis and plasma dyslipidemia induced by a high-sucrose diet are corrected by an acute leptin infusion.
    Huang W; Dedousis N; O'Doherty RM
    J Appl Physiol (1985); 2007 Jun; 102(6):2260-5. PubMed ID: 17363621
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Syndecan-1 promotes Wnt/β-catenin signaling in multiple myeloma by presenting Wnts and R-spondins.
    Ren Z; van Andel H; de Lau W; Hartholt RB; Maurice MM; Clevers H; Kersten MJ; Spaargaren M; Pals ST
    Blood; 2018 Mar; 131(9):982-994. PubMed ID: 29212806
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Multiple factors and pathways involved in hepatic very low density lipoprotein-apoB100 overproduction in Otsuka Long-Evans Tokushima Fatty rats.
    Qin B; Anderson RA; Kuzuya T; Kitaura Y; Shimomura Y
    Atherosclerosis; 2012 Jun; 222(2):409-16. PubMed ID: 22546076
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Syndecan-1 limits the progression of liver injury and promotes liver repair in acetaminophen-induced liver injury in mice.
    Nam EJ; Hayashida K; Aquino RS; Couchman JR; Kozar RA; Liu J; Park PW
    Hepatology; 2017 Nov; 66(5):1601-1615. PubMed ID: 28543100
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Decreased peroxisome proliferator-activated receptor alpha gene expression is associated with dyslipidemia in a rat model of chronic renal failure.
    Mori Y; Hirano T; Nagashima M; Shiraishi Y; Fukui T; Adachi M
    Metabolism; 2007 Dec; 56(12):1714-8. PubMed ID: 17998026
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Heparan sulfate chains of syndecan-1 regulate ectodomain shedding.
    Ramani VC; Pruett PS; Thompson CA; DeLucas LD; Sanderson RD
    J Biol Chem; 2012 Mar; 287(13):9952-9961. PubMed ID: 22298773
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Chondroitin sulfate chains on syndecan-1 and syndecan-4 from normal murine mammary gland epithelial cells are structurally and functionally distinct and cooperate with heparan sulfate chains to bind growth factors. A novel function to control binding of midkine, pleiotrophin, and basic fibroblast growth factor.
    Deepa SS; Yamada S; Zako M; Goldberger O; Sugahara K
    J Biol Chem; 2004 Sep; 279(36):37368-76. PubMed ID: 15226297
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Heparanase-1-induced shedding of heparan sulfate from syndecan-1 in hepatocarcinoma cell facilitates lymphatic endothelial cell proliferation via VEGF-C/ERK pathway.
    Yu S; Lv H; Zhang H; Jiang Y; Hong Y; Xia R; Zhang Q; Ju W; Jiang L; Ou G; Zhang J; Wang S; Zhang J
    Biochem Biophys Res Commun; 2017 Apr; 485(2):432-439. PubMed ID: 28209511
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cell surface heparan sulfate proteoglycans control the response of renal interstitial fibroblasts to fibroblast growth factor-2.
    Clayton A; Thomas J; Thomas GJ; Davies M; Steadman R
    Kidney Int; 2001 Jun; 59(6):2084-94. PubMed ID: 11380810
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Heparanase-enhanced shedding of syndecan-1 by myeloma cells promotes endothelial invasion and angiogenesis.
    Purushothaman A; Uyama T; Kobayashi F; Yamada S; Sugahara K; Rapraeger AC; Sanderson RD
    Blood; 2010 Mar; 115(12):2449-57. PubMed ID: 20097882
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The syndecan-1 heparan sulfate proteoglycan is a viable target for myeloma therapy.
    Yang Y; MacLeod V; Dai Y; Khotskaya-Sample Y; Shriver Z; Venkataraman G; Sasisekharan R; Naggi A; Torri G; Casu B; Vlodavsky I; Suva LJ; Epstein J; Yaccoby S; Shaughnessy JD; Barlogie B; Sanderson RD
    Blood; 2007 Sep; 110(6):2041-8. PubMed ID: 17536013
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Shedding of syndecan-4 promotes immune cell recruitment and mitigates cardiac dysfunction after lipopolysaccharide challenge in mice.
    Strand ME; Aronsen JM; Braathen B; Sjaastad I; Kvaløy H; Tønnessen T; Christensen G; Lunde IG
    J Mol Cell Cardiol; 2015 Nov; 88():133-44. PubMed ID: 26449522
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Disturbed lipids, lipoproteins and triglyceride-rich lipoproteins as well as fasting and nonfasting non-high-density lipoprotein cholesterol in post-renal transplant patients.
    Kimak E; Ksiazek A; Baranowicz-Gaszczyk I; Solski J
    Ren Fail; 2007; 29(6):705-12. PubMed ID: 17763166
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hepatic remnant lipoprotein clearance by heparan sulfate proteoglycans and low-density lipoprotein receptors depend on dietary conditions in mice.
    Foley EM; Gordts PLSM; Stanford KI; Gonzales JC; Lawrence R; Stoddard N; Esko JD
    Arterioscler Thromb Vasc Biol; 2013 Sep; 33(9):2065-74. PubMed ID: 23846497
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Glycobiology of syndecan-1 in bacterial infections.
    Aquino RS; Teng YH; Park PW
    Biochem Soc Trans; 2018 Apr; 46(2):371-377. PubMed ID: 29523771
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Heparanase degrades syndecan-1 and perlecan heparan sulfate: functional implications for tumor cell invasion.
    Reiland J; Sanderson RD; Waguespack M; Barker SA; Long R; Carson DD; Marchetti D
    J Biol Chem; 2004 Feb; 279(9):8047-55. PubMed ID: 14630925
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Apolipoproteins E and AV mediate lipoprotein clearance by hepatic proteoglycans.
    Gonzales JC; Gordts PL; Foley EM; Esko JD
    J Clin Invest; 2013 Jun; 123(6):2742-51. PubMed ID: 23676495
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Plasma concentrations of syndecan-1 are dependent on kidney function.
    Hahn RG; Zdolsek M; Zdolsek J
    Acta Anaesthesiol Scand; 2021 Jul; 65(6):809-815. PubMed ID: 33595099
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The heparanase/syndecan-1 axis in cancer: mechanisms and therapies.
    Ramani VC; Purushothaman A; Stewart MD; Thompson CA; Vlodavsky I; Au JL; Sanderson RD
    FEBS J; 2013 May; 280(10):2294-306. PubMed ID: 23374281
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Heparanase and Syndecan-4 Are Involved in Low Molecular Weight Fucoidan-Induced Angiogenesis.
    Haddad O; Guyot E; Marinval N; Chevalier F; Maillard L; Gadi L; Laguillier-Morizot C; Oudar O; Sutton A; Charnaux N; Hlawaty H
    Mar Drugs; 2015 Oct; 13(11):6588-608. PubMed ID: 26516869
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.